At the time of writing, Climb Bio Inc [CLYM] stock is trading at $4.28, down -2.28%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLYM shares have gain 42.67% over the last week, with a monthly amount glided 132.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on October 13, 2025, and set its price target to $9. On August 15, 2025, Robert W. Baird initiated with a Outperform rating and assigned a price target of $9 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $10 on June 06, 2025. BTIG Research initiated its recommendation with a Buy and recommended $7 as its price target on May 22, 2025. Leerink Partners started tracking with a Outperform rating for this stock on December 02, 2024, and assigned it a price target of $10.
For the past year, the stock price of Climb Bio Inc fluctuated between $1.05 and $4.82. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $4.28 at the most recent close of the market. An investor can expect a potential return of 157.01% based on the average CLYM price forecast.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.06 points at the first support level, and at 3.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.56, and for the 2nd resistance point, it is at 4.85.
Ratios To Look Out For
It is important to note that Climb Bio Inc [NASDAQ:CLYM] has a current ratio of 18.38. In addition, the Quick Ratio stands at 18.38 and the Cash Ratio stands at 3.66.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Dec 11 ’25 when 0.21 million shares were purchased. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Dec 12 ’25 to buy 0.1 million shares. Meanwhile, President and CEO Brennan Aoife sold 20618.0 shares on Jun 30 ’25.
